Payment overview · 2025
General Payments
$3,208.26
114 reported records · 15 companies
Healthcare provider profile · identity verified
John D Wrightson, MD
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation|Pain Medicine · NEW CASTLE, PA · NPI 1861462798
Verified facts
What the public records show
CMS Open Payments records show John D Wrightson, MD received $3,208.26 in general payments during 2025 across 114 reported records.
Abbott Laboratories accounted for 53.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Levorphanol Tartrate, Relistor.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Belbuca by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,708.75 | 53.3% | 32 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $373.36 | 11.6% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $252.69 | 7.9% | 16 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $216.17 | 6.7% | 7 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $195.07 | 6.1% | 18 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $113.41 | 3.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$72.44 | 2.3% | 4 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $71.59 | 2.2% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $57.55 | 1.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $41.81 | 1.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.90 | 1.0% | 2 | 2025 |
| AppliedVR Inc | Unresolved — no canonical attribution shown | $24.45 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.25 | 0.6% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $15.75 | 0.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,208.26 | 114 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $907.44 | 14 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $561.56 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $233.24 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $226.00 | 15 | 2025 |
Source payment records
|
|||||
| Prialt Normalized: prialt |
Drug | TerSera Therapeutics LLC | $216.17 | 7 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $181.13 | 9 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $113.41 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $95.72 | 9 | 2025 |
Source payment records
|
|||||
| LAMITRODE TRIPOLE Normalized: lamitrode tripole |
Device | Abbott Laboratories | $80.84 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $79.86 | 8 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $75.46 | 3 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $71.59 | 4 | 2025 |
Source payment records
|
|||||
| AXIUM Normalized: axium |
Device | Abbott Laboratories | $63.79 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $63.13 | 6 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $53.64 | 3 | 2025 |
Source payment records
|
|||||
| IONICRF Normalized: ionicrf |
Device | Abbott Laboratories | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| OSTEOCOOL RF ABLATION SYSTEM Normalized: osteocool rf ablation system |
Device | Medtronic, Inc. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| RelieVRx Normalized: relievrx |
Device | AppliedVR Inc | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| Nucynta Normalized: nucynta |
Drug | Collegium Pharmaceutical, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| NT2000IX Normalized: nt2000ix |
Device | Abbott Laboratories | $9.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 63 | exact normalized | Medicare Part D |
| LEVORPHANOL TARTRATE levorphanol tartrate |
2025 | Levorphanol Tartrate | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
63 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 638 | 206 |
| Oxycodone Hcl | Oxycodone Hcl | 568 | 186 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 556 | 173 |
| Gabapentin | Gabapentin | 505 | 116 |
| Morphine Sulfate Er | Morphine Sulfate | 204 | 67 |
| Pregabalin | Pregabalin | 199 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 194 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 38 |
| Baclofen | Baclofen | 130 | 30 |
| Xtampza Er | Oxycodone Myristate | 113 | 39 |
| Tramadol Hcl | Tramadol Hcl | 97 | 23 |
| Ibuprofen | Ibuprofen | 96 | 23 |
| Morphine Sulfate | Morphine Sulfate | 91 | 29 |
| Meloxicam | Meloxicam | 84 | 21 |
| Hydromorphone Hcl | Hydromorphone Hcl | 78 | 27 |
| Movantik | Naloxegol Oxalate | 76 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 12 |
| Carisoprodol | Carisoprodol | 68 | 18 |
| Belbuca | Buprenorphine Hcl | 63 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 19 |
| Methocarbamol | Methocarbamol | 54 | suppressed |
| Celecoxib | Celecoxib | 49 | 13 |
| Nabumetone | Nabumetone | 42 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 42 | suppressed |
| Fentanyl | Fentanyl | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 34 |
| Symproic | Naldemedine Tosylate | 40 | suppressed |
| Oxycontin | Oxycodone Hcl | 36 | suppressed |
| Prednisone | Prednisone | 31 | 22 |
| Methadone Hcl | Methadone Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Naproxen | Naproxen | 26 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Savella | Milnacipran Hcl | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Levorphanol Tartrate | Levorphanol Tartrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Relistor | Methylnaltrexone Bromide | 14 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ztlido | Lidocaine | 13 | suppressed |
| Lorazepam | Lorazepam | 12 | 11 |
| Metaxalone | Metaxalone | 12 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,208.26 · 114 records | Abbott Laboratories | AJOVY, AUSTEDO XR, AXIUM, Axonics, Belbuca, ETERNA, General - Pain Management, INSPIRE, IONICRF, Intracept, KYPHON EXPRESS II KYPHOPAK TRAY, LAMITRODE TRIPOLE, LEVORPHANOL TARTRATE, NT2000IX, Nalu Neurostimulation System, Nucynta, OCTRODE, OSTEOCOOL RF ABLATION SYSTEM, PROCLAIM, Prialt, QULIPTA, QUTENZA, RELISTOR, RelieVRx, SYNCHROMEDII, TONMYA, UBRELVY, WaveWriter Alpha Prime 16, XTAMPZA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error